Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available. The purpose of this study is to compare the pharmacokinetics of the two formulations.
Melanoma
DRUG: CP-675,206|DRUG: CP-675,206
Pharmacokinetics: maximum plasma concentration of CP-675,206, 1 hour|Pharmacokinetics: AUC, defined as the area under the concentration -time curve, Time 0 to Day 85
Human-anti-human antibodies, 1 year|Adverse events, 1 year|Safety laboratory tests, 1 year|Proportion of patients alive and free of disease at 1 year, 1 year
This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available. The purpose of this study is to compare the pharmacokinetics of the two formulations.